Nitrogen Double Bonded Directly To Carbon Patents (Class 514/638)
Aldimines or ketimines which contain a benzene ring (i.e., rc=n wherein r is c or h) (Class 514/641)
-
Patent number: 7348319Abstract: The present invention relates to nitric oxide-releasing amidine diazeniundiolates, compositions comprising same, methods of using same, and a method for preparing same from imidate diazeniumdiolates and primary or secondary amines.Type: GrantFiled: August 19, 2005Date of Patent: March 25, 2008Assignee: United States of America as represented by the Department of Health and Human ServicesInventors: Joseph A Hrabie, Larry K Keefer, Ernst V Arnold
-
Publication number: 20080031961Abstract: The present invention relates to benefit agent containing delivery particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions, for example, personal care, cleaning or fabric care compositions, such particles increase the efficiency of benefit agent delivery, there by allowing reduced amounts of benefit agents to be employed. In addition to allowing the amount of benefit agent to be reduced, such particles allow a broad range of benefit agents to be employed.Type: ApplicationFiled: August 1, 2007Publication date: February 7, 2008Inventors: Philip Andrew Cunningham, Jiten Odhavji Dihora, Ziayou Liu, Peggy Dorothy Sands, Sandra Jacqueline Guinebretiere
-
Patent number: 7258850Abstract: Methods are provided for increasing libido and/or treating erectile dysfunction in a man. The methods include the administration of a formulation testosterone alone, another fast-acting drug to treat erectile dysfunction or a combination of the testosterone and the other drug where at least one is delivered by aersolization. The formulation is preferably aerosolized and inhaled into a patient's lungs where particles of testosterone and/or the fast-acting erectile dysfunction drug deposits on lung tissue and then enter the patient's circulatory system.Type: GrantFiled: October 14, 2003Date of Patent: August 21, 2007Assignee: Aradigm CorporationInventors: Reid M. Rubsamen, Robert Cole, James Blanchard, Jeffrey Schuster, Lawrence Linn, John Thipphawong
-
Patent number: 7157017Abstract: The invention relates to control fungal growth on tanned hides, using cyanodithiocarbimates of formula (I): X is a halogen; R is a substituted or unsubstituted C1–C14 alkyl group, a substituted or unsubstituted C2–C14 alkenyl group, a substituted or unsubstituted C2–C14 alkynyl group, a substituted or unsubstituted group defined by Y—Ar—(CH2)m— or by Z—(CH2)n—; Ar is a substituted or unsubstituted aryl group selected from phenyl, or naphthyl; Y is H, halogen, NO2, R1, R1O, R1R2N; Z is NC, R1O, R1OC(O), R1OCH2CH2(OCH2CH2)p m ranges from 0 to 3; n ranges from 0 to 3; p ranges from 0 to 3; and R1 and R2 are independently H, substituted or unsubstituted C1–C5 alkyl.Type: GrantFiled: November 26, 2003Date of Patent: January 2, 2007Assignee: Buckman Laboratories International, Inc.Inventors: Joseph G. E. Fenyes, Thomas E. McNeel, Stephen D. Bryant, Marilyn S. Whittemore, Zoltan G. Csuros, Mark L. Zollinger, Robert H. Miller, Naim B. Miguel
-
Patent number: 7115665Abstract: The present invention relates to the treatment of cancer with compounds that inhibit the activity of endo-exonuclease. Endo-exonuclease has been shown to be necessary for the repair of damaged DNA. Compounds that inhibit the activity of endo-exonuclease have been shown to be particularly effective for treating cancer when used in combination with drugs that induce DNA breaks such as cisplatin and mitomycin C. These compounds have a synergistic effect when used in combination for inhibiting tumour growth. The invention includes pharmaceutical compositions for inhibiting tumour growth comprising a compound that inhibits endo-exonuclease activity. These pharmaceutical compositions preferably include compounds that induce DNA breaks. The invention includes methods of treating cancer with these pharmaceutical compositions and uses of these compositions to treat cancer. The preferred compounds that inhibit the activity of endo-exonuclease have low toxicity. One such compound is pentamidine.Type: GrantFiled: November 16, 2000Date of Patent: October 3, 2006Assignee: Onocozyme Pharma, Inc.Inventors: Terry Chow, Chiaoli Yeh, David Griller, Leonard Yuen
-
Patent number: 7115666Abstract: Disclosed are nitrone compounds and pharmaceutical compositions containing such compounds. The nitrone compounds have one to six additional carbons bridging between the nitrone functionality and the nitrone aryl ring. The disclosed compositions are useful as therapeutics for inflammation-related conditions and analgesia in mammals, such as arthritis, and for neuropathic pain and traumatic injuries such as traumatic brain injury and acute spinal cord injury.Type: GrantFiled: October 14, 2003Date of Patent: October 3, 2006Assignee: Renovis, Inc.Inventors: M. Amin Khan, Ravindra B. Upasani, Paul L. Wood
-
Patent number: 6929685Abstract: The invention relates to methods for preventing the attachment of aquatic organisms to surfaces that are submerged for extension periods of time in water. More particularly, this invention relates to the protection of submerged surfaces with alkylamine derivatives as antifouling agents. The invention is beneficiary for the environment in that it will permit the use of copper- and tin-free paints.Type: GrantFiled: March 27, 2002Date of Patent: August 16, 2005Assignee: Bayer AtiengesellschaftInventors: Daniel Bernard, Jean-Claude Braekman, Gabriele Ferrari, Martin Kugler, Franz Kunisch, Mark Plehiers, Marcel Vos
-
Patent number: 6914078Abstract: Disclosed are compounds having one of the following structures: wherein R and R? are hydrogen or substituted or unsubstituted C1 to C6 linear or branched alkyl, and at least one X is a halogen atom, pharmaceutical compositions containing the compounds as active ingredients, and methods for using the compounds in the photodynamic treatment of cancers.Type: GrantFiled: February 25, 2003Date of Patent: July 5, 2005Assignee: Wisconsin Alumni Research FoundationInventor: Guilherme L. Indig
-
Patent number: 6911478Abstract: The present invention relates to nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions comprising such compounds, methods of using such compounds and compositions, and to a method for the preparation of nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates via the direct reaction of nitric oxide with amidines and enamines, and to a method of converting amines into such compounds.Type: GrantFiled: March 23, 2004Date of Patent: June 28, 2005Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Joseph A. Hrabie, Larry K. Keefer
-
Patent number: 6908948Abstract: A chemical composition and method of use of the composition is described. The chemical composition includes an aza-enediynes, aza-enyne allenes, or an aza-diallenes. These compound are preferably non-hydrolyzable, cationic compounds that bind to nucleic acids. In addition it is believed that these compounds may undergo chemical reactions in the presence of a nucleic acid to generate reactive intermediates that cleave nucleic acids.Type: GrantFiled: July 16, 1999Date of Patent: June 21, 2005Assignee: Research Development FoundationInventors: Sean M. Kerwin, Wendi M. David
-
Patent number: 6903100Abstract: The present invention is directed to the treatment of multiple sclerosis by periodically administering a high dose of methotrexate at a level sufficiently high to cross the blood brain barrier. The methotrexate administration is accompanied by leucovorin rescue of the periphery. The high dose methotrexate is preferably administered at 1 to 4 month intervals. The periodic high dose methotrexate treatment may be used in conjunction with interim treatments using a therapeutic agent that is effective in treating MS, but does not cross the BBB in cytotoxic amounts. It is contemplated that the method of the present invention may be employed to treat other non-infectious, non-neoplastic inflammatory conditions of the CNS.Type: GrantFiled: April 24, 2002Date of Patent: June 7, 2005Assignee: MidAmerica Neuroscience Research FoundationInventor: Vernon D. Rowe
-
Patent number: 6852889Abstract: The invention provides novel adamantane compounds having one of the following formulas: wherein: R1 and R3 are H, OH, alkyl, cycloalkyl, amino or aryl, and can be the same or different; R2 is H, NH2, alkyl, OH, COOH, amino, amide, or carbamate; R4-R8 are H, OH, NH2, alkyl, OH, COOH, ester, amino, amide, or alkyloxy, and can be the same or different; R9-R14 are H, alkyl, or phenyl, and can be the same or different; and wherein when any of R1-R8 is amino, the compounds are the free bases and their acid addition salts. The present invention also relates to compositions and methods for treating and/or preventing neurological and inflammatory disorders in a patient by administering a therapeutically effective amount of the compounds of formula (I), (II) or (III) and a pharmaceutically acceptable carrier.Type: GrantFiled: January 30, 2004Date of Patent: February 8, 2005Assignees: Panorama Research, Inc., NeuroMolecular, Inc.Inventors: Yuqiang Wang, James W. Larrick
-
Patent number: 6815425Abstract: A nueroprotectant composition wherein the active ingredient is pGLU-GLU-PRO-NH2 or a combination of pGLU-GLU-PRO-NH2 (EEP) and N-tert-Butyl-&agr;-(2-sulfophenyl)nitrone (SPBN) or other nitrone. A method of treating and preventing diseases and injuries of the brain, spinal cord and retina is also presented by administering the endogenous tripeptide EEP to a subject as a neuroprotectant or by administering EEP in combination with SPBN or other nitrone.Type: GrantFiled: October 20, 2000Date of Patent: November 9, 2004Assignee: The United States of America as represented by the Secretary of the ArmyInventors: James L. Meyerhoff, Michael L. Koenig, Joseph B. Long
-
Patent number: 6750254Abstract: The present invention relates to nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions comprising such compounds, methods of using such compounds and compositions, and to a method for the preparation of nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates via the direct reaction of nitric oxide with amidines and enamines, and to a method of converting amines into such compounds.Type: GrantFiled: January 22, 2003Date of Patent: June 15, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Joseph A. Hrabie, Larry K. Keefer
-
Patent number: 6686345Abstract: A chemical composition and method of use of the composition is described. The chemical composition includes an aza-enediyne, aza-enyne allene, or an aza-diallene. These compound are preferably non-hydrolyzable, cationic compounds that bind to nucleic acids. In addition it is believed that these compounds may undergo chemical reactions in the presence of a nucleic acid to generate reactive intermediates that cleave nucleic acids.Type: GrantFiled: September 28, 2001Date of Patent: February 3, 2004Assignee: Research Development FoundationInventors: Sean Michael Kerwin, Wendi M. David
-
Patent number: 6653350Abstract: Methods of treating osteoarthritis by administering an therapeutically effective amount of NOS inhibitor are provided.Type: GrantFiled: September 7, 1999Date of Patent: November 25, 2003Assignees: G.D. Searle & Co., Pharmacia CorporationInventors: Pamela T. Manning, Jane R. Connor, Mark G. Currie, Jean Pierre Pelletier, Johanne Martel Pelletier
-
Publication number: 20030162773Abstract: The present invention relates to water-containing formulations for the dermal control of parasitic insects on animals, having the following compositionType: ApplicationFiled: January 17, 2003Publication date: August 28, 2003Inventors: Kirkor Sirinyan, Hubert Dorn, Ulrich Heukamp
-
Patent number: 6569902Abstract: PBN (&agr;-phenyl-tert-butylnitrone), and its derivatives nitrone-based free radical traps, significantly reduce preneoplastic nodule development as well as inhibit hepatocellular carcinoma (HCC) formation at very low levels. The involvement of reactive oxygen species (ROS) in cancer development has been strongly implicated for many years. The involvement of ROS has been strongly implicated in cancer development is a model system where feeding a choline deficiency (CD) diet to rats leads to hepatocellular carcinoma (HCC) development. Administering PBN in the drinking water inhibits HCC formation. Preneoplastic nodule growth in the liver is significantly suppressed by administering PBN, or some of its natural metabolites, in the diet. The effectiveness of PBN in preventing HCC development in the CD liver model is considered due to its prevention of tumor development after the target cells have already been initiated, i.e. genetically changed into tumor cells.Type: GrantFiled: March 28, 2001Date of Patent: May 27, 2003Assignee: Oklahoma Medical Research FoundationInventors: Robert A. Floyd, Yashige Kotake, Kenneth L. Hensley, Dai Nakae
-
Nitromethyl ketone compounds having aldose reduction inhibiting properties and methods for their use
Patent number: 6559185Abstract: The present invention relates to the compounds of formula: in which R1, R2, R3, E, A, X, Z, p and n are as defined herein. These compounds are aldose reductase inhibitors.Type: GrantFiled: November 12, 1999Date of Patent: May 6, 2003Assignee: Merck Patent GmbHInventors: Claude Lardy, Jaques Barbanton, Herve Dumas, Francois Collonges, Philippe Durbin -
Patent number: 6545055Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.Type: GrantFiled: May 24, 2000Date of Patent: April 8, 2003Assignee: Millennium Pharmaceuticals, Inc.Inventors: Bing-Yan Zhu, Ting Su, Zhaozhong Jon Jia, Robert M. Scarborough, Yonghong Song
-
Publication number: 20030027806Abstract: The present invention provides synthetic methods and compositions for treatment of autoimmune and anti-inflammatory disorders comprising administering an effective amount of a derivative of triptolide alone or in combination or alternation with other anti-autoimmune or anti-inflammatory compounds.Type: ApplicationFiled: October 2, 2001Publication date: February 6, 2003Inventors: Susheng Wang, Dennis C. Liotta, James P. Snyder, Hariharan Venkatesan
-
Publication number: 20030022923Abstract: The preparation and use of a protected organic aldehyde is described wherein bioavailability of the orally administered therapeutic aldehyde is improved. The protected aldehyde is prepared by reacting the aldehyde with a protecting group, for example, condensing the aldehyde chemically with a thiazolidine-4-carboxylic acid. The improved bioavailability of such orally administered drugs increases the feasibility of delivering sufficient amounts of vanillin or other therapeutic organic aldehydes in vivo to prevent sickling in sickle cell anemia. Combination therapy is also described wherein a protected organic aldehyde is administered to a subject in treatment of sickle cell anemia in conjunction with one or more other drugs, such as pain killers, used in treatment of the symptoms of sickle cell anemia or sickle cell disease.Type: ApplicationFiled: March 12, 2002Publication date: January 30, 2003Applicant: Medinox, Inc.Inventors: Ching-San Lai, Vassil P. Vassilev, Long-Shiuh Chen
-
Patent number: 6511991Abstract: The present invention relates to nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions comprising such compounds, methods of using such compounds and compositions, and to a method for the preparation of nitric oxide-releasing amidine and enamine derived diazeniumdiolates via the direct reaction of nitric oxide with amidines and enamines, and to a method of converting amines into such compounds.Type: GrantFiled: April 3, 2001Date of Patent: January 28, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Joseph A. Hrabie, Larry K. Keefer
-
Patent number: 6462056Abstract: The invention relates to novel oxazolidine derivatives of the formula in which R1, R2 and R3 have the meanings stated in claim 1, their salts and processes for preparing the compounds according to the invention. The compounds of the formula I act as 5-HT2A antagonists with a 5-HT reuptake-inhibiting, antidepressant or anxiolytic effect and can be used to produce pharmaceuticals.Type: GrantFiled: August 25, 1999Date of Patent: October 8, 2002Assignee: Merck Patent Gesellschaft mit beschrankter HaftungInventors: Henning Böttcher, Helmut Prücher, Hartmut Greiner, Gerd Bartoszyk, Christoph Seyfried
-
Publication number: 20020103168Abstract: The invention provides fungicidal compounds of formula I and salts thereof: 1Type: ApplicationFiled: August 6, 2001Publication date: August 1, 2002Applicant: Aventis CropScience S.A.Inventors: Vincent Gerusz, Darren James Mansfield, Joseph Perez, Jean-Pierre Vors
-
Patent number: 6410600Abstract: The invention relates to novel azines, to a process for their preparation and to their use as fungicides.Type: GrantFiled: October 19, 2000Date of Patent: June 25, 2002Assignee: Bayer AktiengesellschaftInventors: Dirk Backhaus, Bernd-Wieland Krüger, Peter Gerdes, Herbert Gayer, Martin Vaupel, Klaus Stenzel
-
Publication number: 20020065315Abstract: The present invention relates to ion channel modulating agents. More particularly, the present invention relates to a particular class of chemical compounds represented by general Formula (I) and a pharmaceutically acceptable salt or an oxide or a hydrate thereof, that has proven useful as modulators of SKCa, IKCa and BKCa channels. In further aspects, the present invention relates to the use of these SK/IK/BK channel modulating agents for the manufacture of medicaments, and pharmaceutical compositions comprising the SK/IK/BK channel modulating agents. The SK/IK/BK channel modulating agents of the invention are useful for the treatment or alleviation of diseases and conditions associated with the SK/IK/BK channels.Type: ApplicationFiled: November 9, 2001Publication date: May 30, 2002Inventors: Bo Skaaning Jensen, Lene Teuber, Dorte Strobaek, Palle Christophersen, Soren Peter Olesen
-
Patent number: 6395783Abstract: The present invention provides a method for changing addiction-related behavior of a mammal suffering from addiction to phencyclidine (PCP). The method includes administering to the mammal an effective amount of gamma vinylGABA (GVG) or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof, wherein the effective amount is sufficient to diminish, inhibit or eliminate behavior associated with craving or use of PCP.Type: GrantFiled: October 23, 2000Date of Patent: May 28, 2002Assignee: Brookhaven Science Associates, LLCInventors: Stephen L. Dewey, Jonathan D. Brodie, Charles R. Ashby, Jr.
-
Publication number: 20020022638Abstract: This invention provides compounds of Formula I having the structure 1Type: ApplicationFiled: July 12, 2001Publication date: February 21, 2002Applicant: American Home Products CorporationInventors: Mark A. Ashwell, William R. Solvibile
-
Patent number: 6297284Abstract: A chemical composition and method of use of the composition is described. The chemical composition includes an aza-enediyne, aza-enyne allene, or an aza-diallene. These compound are preferably non-hydrolyzable, cationic compounds that bind to nucleic acids. In addition it is believed that these compounds may undergo chemical reactions in the presence of a nucleic acid to generate reactive intermediates that cleave nucleic acids.Type: GrantFiled: March 23, 2000Date of Patent: October 2, 2001Assignee: Research Development FoundationInventors: Sean Michael Kerwin, Wendi M. David, Dalip Kumar
-
Patent number: 6265613Abstract: Phenylacetic acid derivatives of the formula I where the substituents and the indexes have the meanings given in the specification, their salts, their preparation and their use.Type: GrantFiled: February 24, 1998Date of Patent: July 24, 2001Assignee: BASF AktiengesellschaftInventors: Bernd Müller, Hubert Sauter, Herbert Bayer, Wassilios Grammenos, Thomas Grote, Reinhard Kirstgen, Klaus Oberdorf, Franz Röhl, Norbert Götz, Michael Rack, Ruth Müller, Gisela Lorenz, Eberhard Ammermann, Siegfried Strathmann, Volker Harries
-
Patent number: 6187938Abstract: The invention relates to amino acid derivatives of general formula (I), wherein R1 is H or CH3, X is H or NR2R3, wherein R2 is H, CH3, COH or COCH3 and R3 is H, CH3 or COO—Z wherein Z is R2R3 NH+CHR1(CH2)nCOO(CH2)mCH2Y; Y is H, CH3 or NHR4, wherein R4 a COO—NH3+CH2(CH2)mOOC(CH2)nCH3, the meaning of group (CH2)m being selected from alkyls, secondary alkyls, monocycloalkyls, bicycloalkyls and tricycloalkyls having from 4 to 15 carbon atoms and n having a value of from 3 to 14.Type: GrantFiled: December 21, 1999Date of Patent: February 13, 2001Assignee: Bochemie, s.r.o.Inventors: Alexandr Hrabálek, Pavel Dole{haeck over (z)}al, Old{haeck over (r)}ich Farsa, Ale{haeck over (s)} Krebs, Ale{haeck over (s)} Kroutil, Martin Roman, Zde{haeck over (n)}ka {haeck over (S)}klubalová
-
Patent number: 6043281Abstract: The present invention relates to the compounds of formula: ##STR1## in which R.sub.1, R.sub.2, R.sub.3, E, A, X, Z, p and n are as defined herein. These compounds are aldose reductase inhibitors.Type: GrantFiled: February 25, 1999Date of Patent: March 28, 2000Assignee: Merck Patent Gesellschaft mit Beschrankter HaftungInventors: Claude Lardy, Jaques Barbanton, Herve Dumas, Francois Collonges, Philippe Durbin
-
Patent number: 6020374Abstract: A pharmaceutical composition comprising, in admixture with a pharmaceutically acceptable carrier, a therapeutically effective amount of a polyaromatic ring-containing compound, capable of mimicking the physiological activity of insulin or insulin-like growth factor.Type: GrantFiled: May 14, 1998Date of Patent: February 1, 2000Assignee: Ramot University Authority for Applied Research & Industrial Development Ltd.Inventors: Avraham Geier, Hannah Kanety, Avraham Karasik
-
Patent number: 6015828Abstract: This invention relates generally to medical treatment methods. Specifically, the invention relates to methodology for the correction of defective chloride transport by activation of chloride channels of the lung and other epithelia using genetic or chemical modification. These methods relate to the treatment of epithelia with compounds which cause activation of the channel as measured by increased probability (Po) of opening of the channel at physiologically relevant holding potentials. These methods also relate to the treatment of epithelia with gene therapy to introduce chloride channels genes with site mutations which cause activation of the channel as measured by increased probability (Po) of opening of the channel at physiologically relevant holding potentials. These treatments will reduce life-threatening complications frequently found in diseases such as cystic fibrosis. These methods of activation of chloride channels also comprise treatment of chloride channels with amidation reactions.Type: GrantFiled: May 23, 1997Date of Patent: January 18, 2000Inventor: John Cuppoletti
-
Patent number: 5985303Abstract: The invention provides a shelf-life extender for upholding the freshness of food, such as meat, vegetables, fruits, etc., in retail packages or in a refrigerator for an extended period of time. An isothiocyanic acid compound is supported on a matrix such as a natural mucilaginous polysaccharide or a solid organic acid and the supported compound is packaged in synthetic resin film or nonwoven fabric. The invention further provides an aqueous gel composition comprising a specified surfactant, an isothiocyanic acid compound, and a gelling agent and a hydrophobic gel composition comprising a specified hydrophobic dispersion medium, an isothiocyanic acid compound, and a gelling agent.Type: GrantFiled: August 2, 1996Date of Patent: November 16, 1999Inventors: Toru Okada, Kenji Kuranari
-
Patent number: 5981168Abstract: Methods and compositions, useful in the treatment of amyloidosis and conditions and diseases associated therewith, such as Alzheimer's Disease (AD). These methods involve administering to a subject a pharmaceutical composition including one or more agents which modulate APP catabolism and amyloid deposition. Accordingly, the methods and compositions are useful for inhibiting amyloidosis in disorders in which amyloid deposition occurs. The methods are based, at least in part, on modulating catabolism of APP in APP-containing cells through the use of a mobile ionophore, such as carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone, which does not substantially alter the viability of those cells.Type: GrantFiled: May 15, 1998Date of Patent: November 9, 1999Assignee: The University of British ColumbiaInventors: Peter B. Reiner, Bruce P. Connop
-
Patent number: 5728736Abstract: Mammalian hair growth is reduced by applying to the skin a dermatologically acceptable composition including an inhibitor of arginase.Type: GrantFiled: November 29, 1995Date of Patent: March 17, 1998Inventors: Douglas Shander, Margaret Funkhouser, James Henry, Gurpreet Ahluwalia
-
Patent number: 5650444Abstract: A compound of the following structure: ##STR1## wherein, when R.sub.8 =H: R.sub.1 =alkyl, cycloalkyl, arylalkyl, aryl;R.sub.2 =cycloalkyl, aryl, C.sub.3 -C.sub.10 alkyl;X,Y=O, S(O).sub.n, NH;Z=CHO, CO.sub.2 R.sub.3, CONHR.sub.4 R.sub.5, CN, COR.sub.6, H, halo, HCN, NHCONR.sub.4 R.sub.5, CONR.sub.4 OR.sub.5, CONR.sub.4 NR.sub.5 R.sub.6, 1-tetrazole, S(O).sub.n OH, S(O).sub.n NR.sub.3 R.sub.4, C.dbd.NOH, C(.dbd.N(OH)NH.sub.2, OCONR.sub.7 R.sub.6, P(O)(OR.sub.4).sub.2, C(.dbd.N(YR.sub.3))R.sub.4, NH.sub.2, SH, OH, OS(O).sub.2 R.sub.3, C(.dbd.NYC(.dbd.O)R.sub.3)R.sub.4, C(O)CO.sub.2 R.sub.3, C(O)CONR.sub.3 R.sub.4, CH(OH)CO.sub.2 R.sub.3, CHFCO.sub.2 R.sub.3, CF.sub.2 CO.sub.2 R.sub.3, CH(OH)CONR.sub.3 R.sub.4, CF.sub.2 CONR.sub.3 R.sub.4, C.dbd.NNH.sub.2, C(.dbd.NOC(.dbd.O)R.sub.3)R.sub.4, C(.dbd.NNHC(.dbd.O)R.sub.3)R.sub.4, C(.dbd.NOH)R.sub.3, C(.dbd.NNR.sub.3)R.sub.4, NHC(.dbd.O)R.sub.6 or C(O)CONH.sub.2 ;R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.Type: GrantFiled: May 25, 1995Date of Patent: July 22, 1997Assignee: American Home Products CorporationInventors: Thomas J. Caggiano, Joseph Prol, Jr.
-
Patent number: 5594012Abstract: A novel anti-active oxygen agent which comprises as active ingredient an amino acid derivative represented by the following general formula (I): ##STR1## wherein Ar represents a 2-hydroxyphenyl, 2-hydroxy-1-naphthyl or pyridyl group, and one or more of the hydrogen atoms attached to the aromatic ring of these groups may be substituted with a halogen atom, or an alkyl, hydroxyl, hydroxyalkyl, nitro, alkoxyl or carboxyl group; R represents the side chain of an amino acid; X represents --CH.sub.2 --NH-- or --CH.dbd.N--; Y represents a hydrogen atom, --COOR.sup.1, --SO.sub.3 H, --CON(R.sup.2)R.sup.3, --CONHCH(R.sup.5)COOR.sup.4 or --CH.sub.2 OH (where each of R.sup.1 to R.sup.4 represents a hydrogen atom or an alkyl group, and R.sup.5 represents the side chain of an amino acid); and n represents an integer of 0 or 1;or its salt,and which inhibits generation of active oxygen species, has a high safety and can be prepared at relatively low costs.Type: GrantFiled: October 6, 1994Date of Patent: January 14, 1997Assignee: Ajinomoto Co., Inc.Inventors: Manabu Kitazawa, Keiji Iwasaki
-
Patent number: 5591760Abstract: Synergistic microbicidal compositions are disclosed, comprising 4,5-dichloro-2-octyl-3-isothiazolone and one or more known microbicides for more effective, and broader control of microorganisms in various systems.Type: GrantFiled: March 24, 1995Date of Patent: January 7, 1997Assignee: Rohm and Haas CompanyInventor: Jemin C. Hsu
-
Patent number: 5576316Abstract: A method for inhibiting tumor growth rate using creatine or creatine analogs is described. The creatine or creatine analogs are administered to subjects such that tumor growth rate is inhibited. Pharmaceutical compositions containing the creatine or creatine analogs and packaged products also are described.Type: GrantFiled: April 4, 1995Date of Patent: November 19, 1996Assignee: University of PennsylvaniaInventor: Mildred Cohn
-
Patent number: 5543433Abstract: Compounds of the formula I ##STR1## where X is hydrogen, halogen, alkyl, alkoxy, trifluoromethyl, cyano or nitro,Y is an amino, methylamino or dimethylamino group,Z is a group CHCH.sub.3, CHOCH.sub.3 or NOCH.sub.3,R is hydrogen or alkyl,A is hydrogen, alkyl, haloalkyl or cycloalkyl,B is unsubstituted or substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl or the group ##STR2## where W is hydrogen, alkyl, alkoxy, alkylthio, alkylamino or dialkylamino, unsubstituted or substituted aryl or heteroaryl, unsubstituted or substituted aryloxy, arylthio, arylamino or aryl-N-(C.sub.1 -C.sub.6 -alkyl)amino, heteroaryloxy, heteroarylthio, heteroarylamino or heteroaryl-N-(alkyl)amino orA and B, together with the C atom whose substituents they are, are an isocyclic or heterocyclic ring which can also be quinonoid,and fungicides containing these compounds.Type: GrantFiled: June 3, 1994Date of Patent: August 6, 1996Assignee: BASF AktiengesellschaftInventors: Reinhard Doetzer, Hubert Sauter, Herbert Bayer, Franz Roehl, Gisela Lorenz, Eberhard Ammermann, Horst Wingert
-
Patent number: 5489590Abstract: A therapeutic composition derived from a pre-activated photoactive compound and a conveyor for destroying tumor or other pathogenic biological contaminants infecting animal body tissues. The conveyor can either be a matrix support or an antibody. The activation of the photoactive compound to produce the pre-activated photoactive compound is carried out by the use of an activating agent. The pre-activated photoactive compound retains its therapeutic activity subsequent to activation. A method for preparing such a therapeutic composition is disclosed. Methods for treating animal body tissue, either outside the body or inside the body, infected with tumors or other pathogenic biological contaminants are disclosed.Type: GrantFiled: February 3, 1992Date of Patent: February 6, 1996Assignee: Baylor Research FoundationInventors: Kirpal S. Gulliya, Shazib Pervaiz, J. Lester Matthews, Robert M. Dowben, Jospeh T. Newman, Edward Forest
-
Patent number: 5470586Abstract: A method of controlling the attachment of organisms to an underwater surface is disclosed. The method comprises contacting the organisms with a compound of Formula I ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are each independently hydrogen, C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy, halogen, or hydroxyl. Antifouling coatings and cementitious compositions containing a compound of Formula I are also disclosed.Type: GrantFiled: April 11, 1994Date of Patent: November 28, 1995Assignee: Duke UniversityInventor: Donald J. Gerhart
-
Patent number: 5409954Abstract: .alpha.-arylacrylic acid derivatives of the general formula I ##STR1## where X is ethylene or ethenylene; Y is a direct bond or oxygen;R.sup.1 is a mononuclear or dinuclear aromatic system substituted by C.sub.1 -C.sub.4 -alkyl, their preparation, insecticides and fungicides containing them and methods for their use.Type: GrantFiled: October 29, 1993Date of Patent: April 25, 1995Assignee: BASF AktiengesellschaftInventors: Reinhard Kirstgen, Albrecht Harreus, Uwe Kardorff, Thomas Kuekenhoehner, Harald Rang, Gisela Lorenz, Eberhard Ammermann, Christoph Kuenast
-
Patent number: 5405871Abstract: Compounds of the formula ##STR1## wherein each of o and p, independently of the other, is 0, 1, 2, 3, 4 or 5, the radicals R.sub.1 being the same or different when o is greater than 1 and the radicals R.sub.2 being the same or different when p is greater than 1;each of R.sub.1 and R.sub.2, independently of the other, is C.sub.1 -C.sub.4 alkyl, halo-C.sub.1 -C.sub.4 alkyl, halogen, --NO.sub.2, --OH, C.sub.1 -C.sub.4 alkoxy, halo-C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylthio, halo-C.sub.1 -C.sub.4 alkylthio, --O--S(.dbd.O)--R.sub.6, --O--S(.dbd.O).sub.2 --R.sub.6, phenoxy or --N(R.sub.11)SO.sub.2 R.sub.12 and/or two substituents R.sub.1 and/or two substituents R.sub.2 are, independently of one another, together --Y--Z--Y--;R.sub.3 is hydrogen, C.sub.1 -C.sub.4 alkyl or halo-C.sub.1 -C.sub.4 alkyl;R.sub.4 is hydrogen, C.sub.1 -C.sub.4 alkyl, halo-C.sub.1 -C.sub.4 alkyl, unsubstituted phenyl or naphthyl or mono- or di-substituted phenyl or naphthyl;R.sub.5 is --S--R.sub.7, --S(.dbd.O)--R.sub.7, --S(.dbd.O).Type: GrantFiled: April 6, 1994Date of Patent: April 11, 1995Assignee: Ciba-Geigy CorporationInventors: Roger G. Hall, Alfons Pascual, Odd Kristiansen
-
Patent number: 5340837Abstract: Compounds of the formula ##STR1## wherein each of o and p, independently of the other, is 0, 1, 2, 3, 4 or 5, the radicals R.sub.1 being the same or different when o is greater than 1 and the radicals R.sub.2 being the same or different when p is greater than 1;each of R.sub.1 and R.sub.2, independently of the other, is C.sub.1 -C.sub.4 alkyl, halo-C.sub.1 -C.sub.4 alkyl, halogen, --NO.sub.2, --OH, C.sub.1 -C.sub.4 alkoxy, halo-C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylthio, halo-C.sub.1 -C.sub.4 alkylthio, --O--S(.dbd.O)--R.sub.6, --O--S(.dbd.O).sub.2 --R.sub.6, phenoxy or --N(R.sub.11)SO.sub.2 R.sub.12 and/or two substituents R.sub.1 and/or two substituents R.sub.2 are, independently of one another, together --Y--Z--Y--;R.sub.3 is hydrogen, C.sub.1 -C.sub.4 alkyl or halo-C.sub.1 -C.sub.4 alkyl;R.sub.4 is hydrogen, C.sub.1 -C.sub.4 alkyl, halo-C.sub.1 -C.sub.4 alkyl, unsubstituted phenyl or naphthyl or mono- or di-substituted phenyl or naphthyl;R.sub.5 is --S--R.sub.7, --S(.dbd.O)--R.sub.7, --S(.dbd.O).Type: GrantFiled: June 25, 1993Date of Patent: August 23, 1994Assignee: Ciba-Geigy CorporationInventors: Roger G. Hall, Alfons Pascual, Odd Kristiansen
-
Patent number: 5324731Abstract: A method of inhibiting growth, transformation and/or metastasis of mammalian cells, particularly epithelial cells, in which activity of at least one enzyme, which participates in purine metabolism or regulation of nucleotide levels or the relative ratios of their phosphorylated states, is elevated. In particular, a method of inhibiting transformation, growth and/or metastasis of mammalian cells in which a DNA tumor virus, a DNA tumor virus factor or other factor which has an equivalent effect on cells has acted.Type: GrantFiled: November 7, 1990Date of Patent: June 28, 1994Assignee: Amira, Inc.Inventors: Rima Kaddurah-Daouk, James W. Lillie, Jonathan J. Burbaum
-
Patent number: 5177073Abstract: A therapeutic composition derived from a pre-activated photoactive compound and a conveyor for destroying tumor or other pathogenic biological contaminants infecting animal body tissues. The conveyor can either be a matrix support or an antibody. The activation of the photoactive compound to produce the pre-activated photoactive compound is carried out by the use of an activating agent. The pre-activated photoactive compound retains its therapeutic activity subsequent to activation. A method for preparing such a therapeutic composition is disclosed. Methods for treating animal body tissue, either outside the body or inside the body, infected with tumors or other pathogenic biological contaminants are disclosed.Type: GrantFiled: April 13, 1990Date of Patent: January 5, 1993Assignee: Baylor Research InstituteInventors: Kirpal S. Gulliya, Shazib Pervaiz, J. Lester Matthews, Robert M. Dowben, Joseph T. Newman, Edward Forest